U20. Functional Validation & Preclinical Research (FVPR)
Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine. This unit is led by Dr. Ibane Abasolo (Head of FVPR). Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models. FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
09 Oct Directors of Unit 20 and Unit 3, Ibane Abasolo and Miriam Royo, show us the ReachGlio project, which uses nanomedicines to slow glioblastoma growth by targeting tumors in the brain, improving drug delivery through nanoparticles. Barcelona, october 2024. Each year, on October 9th, Nanotechnology Day is celebrated, a discipline dedicated to understanding and utilizing matter at a nanometric scale for purposes such as industrial or medical applications. Nanotechnology plays a fundamental role in many research lines developed at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) and the Vall d’Hebron Research Institute (VHIR). “Our goal is to propose one or more clinical trials in[...] 16 May A new project with the participation of NANBIOSIS Unit 20 pioneers thermosensitive hydrogels for localized ovarian cancer treatment, minimizing side effects and enhancing efficacy. May 2024, VHIR/FVPR/CIBER-BBN (Barcelona). As the world recently commemorated Ovarian Cancer Day, from NANBIOSIS we proudly highlight the groundbreaking work of our collaborators in the fight against this deadly disease. Ovarian cancer stands as the seventh leading cause of cancer-related deaths, with Europe bearing the brunt of its impact, recording over 44,000 fatalities annually. In a bid to revolutionize treatment paradigms and enhance patient outcomes, researchers at the Clinical Biochemistry, Drug Delivery and Therapy (CB-DDT) Group,[...] 01 Mar NANBIOSIS researchers pioneer novel treatments for Lysosomal Storage Diseases utilizing extracellular vesicles and liposomes, offering hope to patients. 1 March 2024, Vall d’Hebron Research Institute/ICMAB-CSIC (Barcelona) Lysosomal Storage Diseases (LSDs) encompass a group of rare disorders caused by mutations in lysosomal proteins. These mutations can lead to dysfunctional proteins responsible for breaking down cellular materials, resulting in the accumulation of deposits. Such accumulations can manifest in various neurological symptoms, ranging from progressive neurodegeneration to severe cognitive impairment. Often emerging in childhood, LSDs tragically culminate in premature death for many patients. Currently, up to 14 subtypes of LSDs can be treated[...] 27 Feb For Rare Disease Day, we raise awareness through 2 events: 1 in Barcelona (Feb 28) & another in Madrid (Feb 29). Collaboration & research in focus. 28-29 February 2024, Rare Disease Day 2024 NANBIOSIS is actively involved in promoting awareness and understanding of rare diseases, Due to their lower incidence, these conditions are often face neglect in medical research and industrial treatment. To spotlight this crucial issue, NANBIOSIS is pleased to announce its participation in two significant events coinciding with Rare Disease Day celebrations. These events will address various aspects of rare and minority diseases research and treatment. Event 1:[...] 12 Feb NANBIOSIS researchers reach intracellular targets with encapsulated antibodies. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona (Spain) and Santiago (Chile) Dr. Abasolo and her team have developed an innovative strategy to combat intracellular oncogenes, notably KRAS, implicated in various deadly cancers. By encapsulating therapeutic antibodies within polymeric micelles, they have successfully facilitated the entry of these antibodies into cancer cells, targeting internal markers. This breakthrough, achieved through international collaboration, represents a significant advancement in cancer treatment and holds promise for addressing other diseases with intracellular targets. These findings provide hope for improved therapies and outcomes in cancer and beyond. Every individual is said to[...] 16 Nov – It is possible to achieve an administration method that improves the effectiveness and increases the safety of drugs for chronic liver disease? -Yes, with nanoparticles! – How? To find an answer, was created the european project NANOSIM (Biodegradable nanoparticles of Simvastatin as new therapeutic tool for chronic liver disease financed in the Joint Transnational Call (2018) led by the Hospital Vall d´Hebron. A translational research proposed as an approach for its use in patients. Until now, the only therapeutic option for patients is to eliminate the etiological agent (or the external promoter of damage), whether it is a virus,[...] 08 Nov 2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...] 30 Jun NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Ibane Ibasolo, has been updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020 (Equipment for setting standardized immunotoxicology assays for the U20 -NANBIOSIS I17 Action of the Investment Plan-) A particle particle analyzer equipment (Exoid) has been inslalled at NANBIOSIS U20 for measurement of the concentration and the size of nanoparticles. The Exoid is the latest instrument from the Izon company to measure the physical characteristics of nanoparticles in electrolytic solution. Based on Tunable Resistive Pulse Sensing (TRPS) principles, the equipment[...]U20. Functional Validation & Preclinical Research (FVPR)
Order requestDescription
Services
Equipments
Active projects
Title
Fundin: Organism
Call: Funding source
Role
ICTS-2017-10-CIBER-2
Acquisition and istallation of infrastrucuture to complemnt Unis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivo Experiment
Ministerio de Economía, Industria y Competitividad (MINECO)
Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)
Coordinator
GA: 720942
SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry
Unión Europea (Comisión Europea)
H2020-NMBP-2016-2017
Coordinator
SAF2017-90810-REDI
Strategic Promotion and coordinated
management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017Coordinator
Other projects
Ref
Title
Funding Organism
Unit Role
RTC-2014-2207-1
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases
MINECO
Participant
Publications
News U20
Nanotechnology to slow down the growth of glioblastomas
Temperature-sensitive hydrogels: A pioneering therapeutic approach for ovarian cancer
Reaching for the unreachable: New efforts to treat Lysosomal Storage Diseases
New upcoming events: The active role of NANBIOSIS in awareness of rare diseases
Polymeric Micelles Delivering Hope: A Revolutionary Strategy to Fight Cancer
The door is now open to a new nanoparticle-based treatment for chronic liver disease
Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.
New equipment adquired to improve NANBIOSIS U20